(AIM: SAR) |
24 November 2009 |
SAREUM HOLDINGS PLC
("Sareum" or the "Company")
Holdings in Company
The Company has been notified today that, following a sale of shares, Mr and Mrs Leonard Licht hold 56,700,000 ordinary shares in the capital of the Company, equivalent to 4.82 per cent. of the issued share capital of the Company.
Enquires:
Sareum Holdings plc |
|
Tim Mitchell |
01223 497 700 |
|
|
Merchant John East Securities Limited (Nominated Adviser) |
|
Simon Clements/Bidhi Bhoma |
020 7628 2200 |
|
|
Hybridan LLP (Broker) |
|
Claire Noyce/Stephen Austin |
020 3159 5085 |
Notes for editors:
About Sareum Holdings plc
Sareum is a drug discovery company, headquartered in Cambridge UK, that is focused on producing targeted small molecule therapeutics to address unmet medical needs, primarily in cancer.
Sareum aims to successfully deliver drug candidates for licensing to pharmaceutical and biotechnology companies at the pre-clinical or early clinical trials stage.
Sareum Holdings plc joined the AIM market of the London Stock Exchange in October 2004, trading under the symbol SAR. For further information, please visit www.sareum.co.uk